Myostatin Inhibitor Antibodies UK: Research-Grade Antibodies

Four monoclonal antibodies that act on the myostatin pathway, the signalling system that limits skeletal muscle growth. Each is supplied as a 150 mg research-grade vial with the manufacturer's lot certificate, for laboratory research only. These are biologics, not peptides, and are handled differently from the rest of the range.

In brief: Myostatin inhibitors block the signals that hold skeletal muscle mass down. ALTA PEPTIDES stocks four research-grade monoclonal antibodies on that pathway, each as a 150 mg vial: bimagrumab, apitegromab, trevogrumab and garetosmab, with the certificate of analysis pending for Trevogrumab, Garetosmab, Apitegromab and Bimagrumab, dispatched the same working day before 1pm. They are not the originator companies' products, are unlicensed in the UK, and are supplied strictly for laboratory research.

The myostatin antibodies range compared

The myostatin pathway

Myostatin, also called GDF8, is made by muscle and acts as its main brake. It belongs to the TGF-beta superfamily and signals through the activin type II receptors, ActRIIA and ActRIIB, which it shares with activin A and several related ligands. Animals born without working myostatin carry far more muscle than normal, which is why blocking the pathway has been studied for decades in muscle-wasting disease, ageing and, more recently, weight loss on GLP-1 drugs. A myostatin inhibitor can act at three points: on mature myostatin, on myostatin before it is activated, or on the receptor that all these ligands share. The four antibodies here cover all three. Our myostatin inhibitors explained article walks through the pathway in more detail.

The four antibodies

Bimagrumab binds the activin type II receptors themselves, so it blocks myostatin, activin A and related ligands at once; it has the largest effect on body composition of the four and the most obesity data, from the 72-week BELIEVE trial with semaglutide. Apitegromab binds myostatin in its latent, inactive forms and stops it being switched on, which makes it the most selective; its originator product is approved in the United States for spinal muscular atrophy. Trevogrumab binds mature myostatin and was tested with semaglutide in the COURAGE trial. Garetosmab binds activin A instead, was developed for fibrodysplasia ossificans progressiva, and appeared in obesity research only as the third arm of the COURAGE triplet.

What the trials with GLP-1 drugs found

The reason these antibodies are now searched alongside retatrutide and tirzepatide is muscle. Weight lost on a GLP-1 drug is typically about a quarter to a third lean mass. In COURAGE, adding trevogrumab to semaglutide prevented about half of the lean mass loss over 26 weeks; in EMBRAZE, apitegromab with tirzepatide kept 54.9% of the lean mass that would otherwise have gone; in BELIEVE, bimagrumab with semaglutide produced weight loss that was 92.8% fat. None of these changed total weight loss much on its own; they changed what the weight was made of. Our muscle loss on GLP-1 peptides article covers why that matters, and the safety record is set out on each product page, including the higher discontinuation rate in the COURAGE triplet and the fracture signal in the SMA trial.

Research-grade antibodies, not originator products

The originator antibodies from Lilly, Regeneron and Scholar Rock are not sold outside clinical trials or prescription supply. What ALTA PEPTIDES supplies are research-grade antibodies: recombinant monoclonal antibodies produced by a third-party manufacturer for laboratory work. Each lot comes with the manufacturer's certificate of analysis, published on our certificates page, and identity and purity for an antibody are shown by methods such as SEC-HPLC and SDS-PAGE. A 150 mg vial of a cell-culture antibody costs far more to make than a synthetic peptide, which is reflected in the price, and the stack discount does not apply to antibodies.

Choosing between them

For receptor-level blockade of every ligand at once, the research tool is bimagrumab. For myostatin alone, apitegromab (latent form, most selective) and trevogrumab (mature form) are the two options; garetosmab isolates activin A and is the natural control or partner for a myostatin-only design. All four are monoclonal antibodies of about 150 kDa: store them as the manufacturer's label directs, never shake them, and avoid repeated freezing and thawing. Incretin-receptor agonists for combination designs, such as retatrutide, are in weight and metabolic.

Buying in the UK

None of these antibodies is a controlled substance in the UK and none is licensed here. They are research-grade antibodies supplied strictly as laboratory reagents for in-vitro research, not for human or veterinary use.

Everything on this page is held in UK stock and dispatched the same working day before 1pm Monday to Friday by Royal Mail Tracked 48 (£4.95, free over £75) in plain packaging. Certificates: pending for Trevogrumab, Garetosmab, Apitegromab and Bimagrumab. That is the manufacturer's or supplier's paperwork published as received; ALTA's own independent test of each lot is added to the certificates page as it arrives. Any two of the single-compound vials here earn 10% off the peptide lines automatically, three earn 15% and four or more earn 20%; the stack builder shows the tiers.

Questions

Guides for this category

• Myostatin inhibitors explained: the pathway, the antibodies and why muscle matters in GLP-1 weight lossA myostatin inhibitor is anything that blocks the signal telling muscle to stay small. Four monoclonal antibodies are now in trials alongside GLP-1 drugs to stop the muscle loss that comes with rapid weight loss. What the pathway is, what each antibody does, what came before, and why none of them is available outside a clinical trial.
• Trevogrumab and garetosmab: the COURAGE results, side effects, and when they could be availableTrevogrumab (REGN1033) is Regeneron's fully human antibody against myostatin (GDF8). In the phase 2 COURAGE trial it prevented about half of the lean mass lost on semaglutide, and with garetosmab added it prevented more, at the cost of far more discontinuations and two deaths in the triplet arm. The figures, the safety record and where it stands.
• Garetosmab: Regeneron's anti-activin A antibody, from FOP to the obesity tripletGaretosmab is Regeneron's antibody against activin A, approved by the FDA in August 2026 for adults with fibrodysplasia ossificans progressiva after the phase 3 OPTIMA trial cut new bone lesions by 90% or more. It is also the third component of the COURAGE obesity triplet, where it improved body composition but was linked to high discontinuation and two deaths. What the trials report.
• Bimagrumab: what it is, the BELIEVE results, side effects, price and when it could reach the UKBimagrumab is a monoclonal antibody that blocks the activin type II receptors, owned by Eli Lilly since its 2023 purchase of Versanis. In the phase 2b BELIEVE trial with semaglutide it produced 22.1% weight loss at 72 weeks with 92.8% of it from fat, and on its own it lost fat while adding lean mass. Its history at Novartis, the tirzepatide trials, and a plain statement for anyone searching 'bimagrumab buy'.
• Muscle loss on GLP-1 peptides: what the DXA substudies say for semaglutide, tirzepatide and retatrutideIn the DXA substudies of their own trials, semaglutide lost 9.7% of lean body mass alongside 19.3% of fat, tirzepatide lost 10.9% of lean mass alongside 33.9% of fat, and retatrutide's lean share was reported as consistent with other treatments. Across trials, a quarter to a third of the weight lost on these drugs is lean tissue. The figures per drug, what lean mass is and is not, and the antibody trials built to change the ratio.
• Apitegromab explained: the first approved muscle-protecting antibody, and what it means for weight lossApitegromab is Scholar Rock's antibody that stops the body's main muscle brake, myostatin, from switching on. It became the first drug of its kind ever approved, for the muscle-wasting disease SMA in the US in September 2026. In obesity it doesn't add weight loss: with tirzepatide, it made more of the weight lost come from fat and less from muscle. What it is, what the trials show, and whether you can get it.

Other research areas

• Weight & Metabolic: GLP-1 family and mitochondrial peptides studied for energy balance and metabolism.
• Recovery & Repair: Peptides studied in tissue, tendon and gut models.
• Copper & Skin: GHK-Cu and copper-peptide stacks studied in dermal and wound models.
• Brain & Focus: Nootropic peptides from the Russian literature, supplied as lyophilised powder.
• Growth Hormone: GHRH analogues and secretagogues studied for pulsatile GH release.
• Longevity & Cellular: Peptides studied in ageing, telomere and mitochondrial research.
• Libido & Tanning: Melanocortin receptor agonists.
• Sleep: Delta sleep-inducing peptide.
• Water & Accessories: Bacteriostatic water, syringes and swabs for reconstitution.

Related: certificates of analysis, peptide calculator, build a stack, FAQ, all research peptides.